8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 13, 2026·SEC
Castle Biosciences, Inc.(CSTL)Earnings, Financials & Key Ratios
CSTL•NASDAQ
Price updated Jun 19, 2026
AboutCastle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.Show more
- Revenue$344M+3.7%
- EBITDA-$2M-108.3%
- Net Income-$24M-232.4%
- EPS (Diluted)-0.83-233.9%
- Gross Margin79.37%-3.1%
- EBITDA Margin-0.59%-108.0%
- Operating Margin-12.44%-576.3%
- Net Margin-7.02%-227.7%
- ROE-5.21%-221.0%
CSTL Key Insights
Castle Biosciences, Inc. (CSTL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 40.6%
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Profits declining 18.6% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CSTL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CSTL Price & Volume
Castle Biosciences, Inc. (CSTL) stock price & volume — 10-year historical chart
Loading chart...
CSTL Growth Metrics
Castle Biosciences, Inc. (CSTL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years40.6%
3 Years35.94%
TTM-2.06%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-153.15%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-126.5%
Return on Capital
10 Years-35%
5 Years-9.97%
3 Years-7.77%
Last Year-8.63%
CSTL Recent Earnings
Castle Biosciences, Inc. (CSTL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 12/12 qtrs (100%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.49+0.0%
$0.49
Rev
$84M+6.3%
$79M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.08+65.2%
$0.23
Rev
$87M+8.9%
$80M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.02+94.1%
$0.34
Rev
$83M+3.3%
$80M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.15+129.4%
$0.51
Rev
$86M+26.7%
$68M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.49vs $0.49+0.0% | $84Mvs $79M+6.3% |
| Q1 2026 | Feb 26, 2026 | $0.08vs $0.23+65.2% | $87Mvs $80M+8.9% |
| Q4 2025 | Nov 3, 2025 | $0.02vs $0.34+94.1% | $83Mvs $80M+3.3% |
| Q3 2025 | Aug 4, 2025 | $0.15vs $0.51+129.4% | $86Mvs $68M+26.7% |
Based on last 12 quarters of dataView full earnings history →
CSTL Peer Comparison
Castle Biosciences, Inc. (CSTL) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 VCYT | 4.28B | 53.63 | 65.40 | 16.01% | 16.25% | 6.86% | 0.03 | |
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 FLGT | 535.45M | 18.00 | -9.14 | 13.83% | -18.75% | -5.42% | 0.00 | |
 GH | 17.47B | 131.78 | -39.69 | 32.88% | -40.1% | |||
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 |
Compare CSTL vs Peers
Castle Biosciences, Inc. (CSTL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CSTL Income Statement
Castle Biosciences, Inc. (CSTL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 13.75M | 22.79M | 51.87M | 62.65M | 94.08M | 137.04M | 219.79M | 332.07M | 344.23M | 339.92M |
Revenue Growth % | - | 65.67% | 127.62% | 20.79% | 50.18% | 45.65% | 60.38% | 51.09% | 3.66% | -2.06% |
Cost of Goods Sold | 4.92M | 5.3M | 7.31M | 9.69M | 15.82M | 32.01M | 44.98M | 60.2M | 71.03M | 54.65M |
COGS % of Revenue | 35.79% | 23.25% | 14.09% | 15.46% | 16.82% | 23.36% | 20.47% | 18.13% | 20.63% | - |
Gross Profit | 8.83M▲ 0% | 17.49M▲ 98.0% | 44.55M▲ 154.8% | 52.96M▲ 18.9% | 78.26M▲ 47.8% | 105.03M▲ 34.2% | 174.81M▲ 66.4% | 271.86M▲ 55.5% | 273.2M▲ 0.5% | 201.6M▲ 0% |
Gross Margin % | 64.21% | 76.75% | 85.91% | 84.54% | 83.18% | 76.64% | 79.53% | 81.87% | 79.37% | 59.31% |
Gross Profit Growth % | - | 98.02% | 154.76% | 18.87% | 47.77% | 34.2% | 66.43% | 55.52% | 0.49% | - |
Operating Expenses | 19.73M | 21.32M | 37.23M | 59.51M | 118.34M | 177.88M | 242.78M | 263.19M | 316.01M | 318.56M |
OpEx % of Revenue | 143.46% | 93.59% | 71.78% | 94.98% | 125.78% | 129.81% | 110.46% | 79.26% | 91.8% | - |
Selling, General & Admin | 15.26M | 16.47M | 29.84M | 48.13M | 86.74M | 143M | 180.15M | 200.05M | 229.32M | 235.6M |
SG&A % of Revenue | 110.94% | 72.28% | 57.54% | 76.83% | 92.19% | 104.35% | 81.97% | 60.24% | 66.62% | - |
Research & Development | 4.47M | 4.85M | 7.38M | 13.26M | 29.65M | 44.9M | 53.62M | 52.04M | 51.85M | 53.69M |
R&D % of Revenue | 32.52% | 21.3% | 14.24% | 21.16% | 31.51% | 32.77% | 24.4% | 15.67% | 15.06% | - |
Other Operating Expenses | 163.29K | 0 | 0 | -1.88M | 1.96M | -10.02M | 9.01M | 11.11M | 34.84M | 4M |
Operating Income | -10.9M▲ 0% | -3.84M▲ 64.8% | 7.33M▲ 291.1% | -6.54M▼ 189.3% | -40.08M▼ 512.6% | -72.86M▼ 81.8% | -67.98M▲ 6.7% | 8.67M▲ 112.8% | -42.81M▼ 593.8% | -29.3M▲ 0% |
Operating Margin % | -79.25% | -16.83% | 14.13% | -10.44% | -42.6% | -53.16% | -30.93% | 2.61% | -12.44% | -8.62% |
Operating Income Growth % | - | 64.81% | 291.05% | -189.27% | -512.64% | -81.78% | 6.7% | 112.75% | -593.77% | - |
EBITDA | -10.59M | -3.51M | 7.69M | -6.07M | -36.67M | -62.31M | -55.65M | 24.67M | -2.04M | -16.47M |
EBITDA Margin % | -76.99% | -15.42% | 14.82% | -9.69% | -38.98% | -45.47% | -25.32% | 7.43% | -0.59% | -4.85% |
EBITDA Growth % | - | 66.83% | 318.81% | -178.97% | -504.15% | -69.92% | 10.7% | 144.33% | -108.27% | -157.53% |
D&A (Non-Cash Add-back) | 310.82K | 323.02K | 358K | 472K | 3.41M | 10.54M | 12.33M | 16M | 40.77M | 12.82M |
EBIT | -10.71M | -4.08M | 9.92M | -7.57M | -40.01M | -68.89M | -57.35M | 22.14M | -29.43M | -17.61M |
Net Interest Income | -1.62M | -2.25M | -4.26M | -2.26M | 67K | 3.95M | 10.61M | 12.34M | 11.69M | 8.6M |
Interest Income | 26.18K | 23.51K | 312K | 373K | 68K | 3.97M | 10.62M | 12.92M | 11.77M | 11.22M |
Interest Expense | 1.65M | 2.27M | 4.57M | 2.63M | 1K | 17K | 11K | 577K | 86K | -65K |
Other Income/Expense | -1.46M | -2.52M | -1.98M | -3.66M | 67K | 3.95M | 10.61M | 12.89M | 13.3M | 11.64M |
Pretax Income | -12.36M▲ 0% | -6.36M▲ 48.6% | 5.35M▲ 184.1% | -10.2M▼ 290.7% | -40.01M▼ 292.3% | -68.9M▼ 72.2% | -57.37M▲ 16.7% | 21.56M▲ 137.6% | -29.51M▼ 236.9% | -17.66M▲ 0% |
Pretax Margin % | -89.86% | -27.91% | 10.31% | -16.28% | -42.53% | -50.28% | -26.1% | 6.49% | -8.57% | -5.19% |
Income Tax | 9.73K | 8.61K | 72K | 84K | -8.72M | -1.77M | 101K | 3.32M | -5.36M | -4.82M |
Effective Tax Rate % | -0.08% | -0.14% | 1.35% | -0.82% | 21.79% | 2.56% | -0.18% | 15.39% | 18.15% | 27.32% |
Net Income | -12.37M▲ 0% | -6.37M▲ 48.5% | 5.28M▲ 182.9% | -10.28M▼ 294.9% | -31.29M▼ 204.3% | -67.14M▼ 114.6% | -57.47M▲ 14.4% | 18.25M▲ 131.7% | -24.16M▼ 232.4% | -12.83M▲ 0% |
Net Margin % | -89.93% | -27.94% | 10.17% | -16.42% | -33.26% | -48.99% | -26.15% | 5.49% | -7.02% | -3.77% |
Net Income Growth % | - | 48.53% | 182.88% | -294.88% | -204.28% | -114.55% | 14.41% | 131.75% | -232.41% | -153.15% |
Net Income (Continuing) | -12.37M | -6.37M | 5.28M | -10.28M | -31.29M | -67.14M | -57.47M | 18.25M | -24.16M | -12.83M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.26▲ 0% | -0.60▲ 52.4% | -0.21▲ 65.0% | -0.54▼ 157.1% | -1.24▼ 129.6% | -2.58▼ 108.1% | -2.14▲ 17.1% | 0.62▲ 129.0% | -0.83▼ 233.9% | -0.43▲ 0% |
EPS Growth % | - | 52.38% | 65% | -157.14% | -129.63% | -108.06% | 17.05% | 128.97% | -233.87% | -126.5% |
EPS (Basic) | -1.26 | -0.60 | 0.35 | -0.54 | -1.24 | -2.58 | -2.14 | 0.66 | -0.83 | - |
Diluted Shares Outstanding | 9.78M | 10.65M | 8.66M | 18.93M | 25.14M | 26.05M | 26.8M | 29.25M | 28.99M | 29.89M |
Basic Shares Outstanding | 9.78M | 10.65M | 8.58M | 18.93M | 25.14M | 26.05M | 26.8M | 27.78M | 28.99M | 29.89M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CSTL Balance Sheet
Castle Biosciences, Inc. (CSTL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 6.68M | 18.13M | 116.68M | 429.59M | 353.74M | 292.29M | 295.63M | 360.15M | 361.1M | 328.9M |
Cash & Short-Term Investments | 1.21M | 4.48M | 98.84M | 409.85M | 329.63M | 258.63M | 243.1M | 293.13M | 299.5M | 261.69M |
Cash Only | 1.21M | 4.48M | 98.84M | 409.85M | 329.63M | 122.95M | 98.84M | 119.71M | 116.73M | 63.76M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 135.68M | 144.26M | 173.42M | 182.78M | 197.92M |
Accounts Receivable | 4.65M | 12.09M | 14.65M | 12.76M | 17.28M | 23.48M | 38.3M | 51.22M | 43.38M | 42.26M |
Days Sales Outstanding | 123.46 | 193.67 | 103.09 | 74.34 | 67.05 | 62.53 | 63.61 | 56.3 | 46 | 50.32 |
Inventory | 304.58K | 882.23K | 1.24M | 2.22M | 2.02M | 3.98M | 7.94M | 8.13M | 10.25M | 10.46M |
Days Inventory Outstanding | 22.59 | 60.79 | 61.77 | 83.55 | 46.62 | 45.38 | 64.44 | 49.32 | 52.69 | 63.01 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 6.21M | 6.29M | 7.67M | 7.96M | 14.49M |
Total Non-Current Assets | 3.14M | 4.28M | 3.06M | 9.73M | 108.83M | 155.04M | 157.71M | 171.08M | 217.46M | 218.9M |
Property, Plant & Equipment | 1.47M | 1.53M | 2.06M | 7.1M | 16.88M | 26.5M | 37.74M | 62.71M | 112.24M | 115.36M |
Fixed Asset Turnover | 9.36x | 14.90x | 25.18x | 8.82x | 5.57x | 5.17x | 5.82x | 5.30x | 3.07x | 3.26x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 10.69M | 10.69M | 10.69M | 99.57M | 97.35M |
Intangible Assets | 40.12K | 4.17K | 0 | 0 | 88.92M | 115.66M | 106.64M | 95.54M | 0 | 0 |
Long-Term Investments | 1.56M | 2.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1.63M | 2.75M | 1M | 2.63M | 3.02M | 2.2M | 2.63M | 2.15M | 5.65M | 6.2M |
Total Assets | 9.82M▲ 0% | 22.4M▲ 128.1% | 119.75M▲ 434.5% | 439.33M▲ 266.9% | 462.57M▲ 5.3% | 447.33M▼ 3.3% | 453.34M▲ 1.3% | 531.24M▲ 17.2% | 578.56M▲ 8.9% | 547.8M▲ 0% |
Asset Turnover | 1.40x | 1.02x | 0.43x | 0.14x | 0.20x | 0.31x | 0.48x | 0.63x | 0.59x | 0.61x |
Asset Growth % | - | 128.15% | 434.46% | 266.88% | 5.29% | -3.3% | 1.34% | 17.18% | 8.91% | 39.25% |
Total Current Liabilities | 5.22M | 6.74M | 15.29M | 20.88M | 24.89M | 36.13M | 47.67M | 49.39M | 68.68M | 48.76M |
Accounts Payable | 1.12M | 1.45M | 1.86M | 2.1M | 2.55M | 4.73M | 10.27M | 6.9M | 18.71M | 15.04M |
Days Payables Outstanding | 82.82 | 99.99 | 93.12 | 79.07 | 58.73 | 53.95 | 83.32 | 41.84 | 96.15 | 98.76 |
Short-Term Debt | 1M | 0 | 5.83M | 0 | 0 | 0 | 0 | 278K | 1.74M | 2.92M |
Deferred Revenue (Current) | 9.73K | 0 | 0 | 6.62M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 706.64K | 6M | 10M | 16.91M | 25.67M | 30.69M | 774K | 48.22M | 30.8M |
Current Ratio | 1.28x | 2.69x | 7.63x | 20.58x | 14.21x | 8.09x | 6.20x | 7.29x | 5.26x | 6.75x |
Quick Ratio | 1.22x | 2.56x | 7.55x | 20.47x | 14.13x | 7.98x | 6.04x | 7.13x | 5.11x | 6.53x |
Cash Conversion Cycle | 63.23 | 154.47 | 71.73 | 78.82 | 54.93 | 53.96 | 44.73 | 63.78 | 2.54 | 14.57 |
Total Non-Current Liabilities | 18.87M | 25.74M | 19.34M | 2.76M | 25.95M | 12.05M | 14.4M | 26.01M | 39.01M | 37.63M |
Long-Term Debt | 17.6M | 24.5M | 19.29M | 0 | 0 | 0 | 0 | 9.74M | 35.17M | 33.8M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 7.02M | 11.62M | 14.2M | 14.66M | 0 | 51.38M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 635K | 428K | 206K | 1.61M | 2.33M | 7.79M |
Other Non-Current Liabilities | 1.27M | 1.24M | 55K | 1.03M | 18.29M | 0 | 0 | 0 | 1.5M | 1.5M |
Total Liabilities | 24.09M | 32.47M | 34.63M | 23.64M | 50.83M | 48.18M | 62.07M | 75.4M | 107.68M | 86.39M |
Total Debt | 18.6M | 24.5M | 25.12M | 0 | 8.2M | 13.4M | 15.34M | 26.34M | 36.91M | 36.72M |
Net Debt | 17.39M | 20.02M | -73.72M | -409.85M | -321.43M | -109.55M | -83.51M | -93.36M | -79.82M | -27.04M |
Debt / Equity | - | - | 0.30x | - | 0.02x | 0.03x | 0.04x | 0.06x | 0.08x | 0.08x |
Debt / EBITDA | - | - | 3.27x | - | - | - | - | 1.07x | - | -2.23x |
Net Debt / EBITDA | - | - | -9.59x | - | - | - | - | -3.79x | - | 1.64x |
Interest Coverage | -6.49x | -1.80x | 2.17x | -2.87x | -40011.00x | -4052.18x | -5214.00x | 38.37x | -342.19x | 270.94x |
Total Equity | -14.27M▲ 0% | -10.07M▲ 29.4% | 85.11M▲ 945.3% | 415.69M▲ 388.4% | 411.74M▼ 1.0% | 399.15M▼ 3.1% | 391.27M▼ 2.0% | 455.83M▲ 16.5% | 470.87M▲ 3.3% | 461.42M▲ 0% |
Equity Growth % | - | 29.44% | 945.28% | 388.4% | -0.95% | -3.06% | -1.97% | 16.5% | 3.3% | 21.41% |
Book Value per Share | -1.46 | -0.95 | 9.83 | 21.96 | 16.38 | 15.32 | 14.60 | 15.58 | 16.24 | 15.44 |
Total Shareholders' Equity | -14.27M | -10.07M | 85.11M | 415.69M | 411.74M | 399.15M | 391.27M | 455.83M | 470.87M | 461.42M |
Common Stock | 1.9K | 1.92K | 17K | 25K | 25K | 27K | 27K | 28K | 30K | 30K |
Retained Earnings | -51.12M | -57.49M | -52.21M | -62.5M | -93.77M | -160.91M | -218.37M | -200.13M | -224.28M | -238.81M |
Treasury Stock | -809.6K | -2.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -638.47K | -909.38K | 0 | 0 | 0 | -381K | 136K | 230K | 267K | -63K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CSTL Cash Flow Statement
Castle Biosciences, Inc. (CSTL) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -12.23M | -12.29M | 7.01M | 9.87M | -18.98M | -41.66M | -5.63M | 64.87M | 64.35M | 48.25M |
Operating CF Margin % | -88.95% | -53.96% | 13.53% | 15.75% | -20.18% | -30.4% | -2.56% | 19.53% | 18.69% | - |
Operating CF Growth % | - | -0.5% | 157.06% | 40.63% | -292.43% | -119.43% | 86.49% | 1252.97% | -0.8% | -272.35% |
Net Income | -12.37M | -6.37M | 5.28M | -10.28M | -31.29M | -67.14M | -57.47M | 18.25M | -24.16M | -12.83M |
Depreciation & Amortization | 310.82K | 323.02K | 358K | 472K | 3.41M | 10.54M | 12.33M | 16M | 40.77M | 14.94M |
Stock-Based Compensation | 108.7K | 293.64K | 1.25M | 8.31M | 21.74M | 36.32M | 51.22M | 50.32M | 45.89M | 34.71M |
Deferred Taxes | -163.29K | 272.42K | -2.28M | 0 | -8.74M | -1.88M | -223K | 1.4M | -6.23M | -5.47M |
Other Non-Cash Items | 520.23K | 542.37K | 2.37M | 2.22M | 0 | -19.5M | -4.86M | -6.97M | -5.53M | 2.28M |
Working Capital Changes | -640.51K | -7.36M | 44K | 9.15M | -4.1M | -7K | -6.63M | -14.13M | 13.6M | 14.62M |
Change in Receivables | -428.21K | -8.41M | -896K | 1.66M | -4.63M | -6.22M | -14.93M | -12.64M | 6.88M | 13.17M |
Change in Inventory | -115.56K | -577.66K | -355K | -980K | 327K | -1.68M | -3.96M | -193K | -2.14M | -3.63M |
Change in Payables | 370.9K | 197.25K | 557K | 169K | -182K | 582K | 5.71M | -4.37M | 3.08M | 5.66M |
Cash from Investing | -494.85K | -277.04K | -937K | -4.75M | -66.66M | -166.54M | -16.18M | -50.14M | -60.37M | -63.74M |
Capital Expenditures | -494.85K | -277.04K | -937K | -4.75M | -3.48M | -5.63M | -13.62M | -28.33M | -36.02M | -43.74M |
CapEx % of Revenue | 3.6% | 1.22% | 1.81% | 7.58% | 3.7% | 4.11% | 6.2% | 8.53% | 10.46% | 12.87% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | -26.97M | 0 | 18K | -18.73M | -18.7M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 3K | -63.17M | 742K | 13K | 0 | -7.64M | -2.1M |
Cash from Financing | 8.87M | 15.84M | 88.29M | 305.89M | 5.42M | 1.51M | -2.3M | 6.14M | -6.96M | -10.44M |
Debt Issued (Net) | 8.57M | 5.42M | 20.92M | -27.36M | -8K | -122K | -142K | 9.9M | -115K | -139K |
Equity Issued (Net) | 289.16K | 10.42M | 65.98M | 330.04M | 0 | 0 | 0 | 2.02M | 2.21M | 2.51M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 3.55K | 0 | 1.39M | 3.21M | 5.43M | 1.64M | -2.16M | -5.78M | -9.05M | -12.81M |
Net Change in Cash | -3.86M▲ 0% | 3.27M▲ 184.6% | 94.37M▲ 2788.9% | 311.01M▲ 229.6% | -80.22M▼ 125.8% | -206.69M▼ 157.7% | -24.11M▲ 88.3% | 20.87M▲ 186.6% | -2.98M▼ 114.3% | -25.93M▲ 0% |
Free Cash Flow | -12.73M▲ 0% | -12.57M▲ 1.2% | 6.08M▲ 148.3% | 5.11M▼ 15.9% | -22.47M▼ 539.3% | -47.29M▼ 110.5% | -19.25M▲ 59.3% | 36.54M▲ 289.8% | 28.33M▼ 22.5% | 4.52M▲ 0% |
FCF Margin % | -92.54% | -55.17% | 11.72% | 8.16% | -23.88% | -34.51% | -8.76% | 11% | 8.23% | 1.33% |
FCF Growth % | - | 1.23% | 148.35% | -15.86% | -539.3% | -110.48% | 59.3% | 289.85% | -22.48% | -89.18% |
FCF per Share | -1.30 | -1.18 | 0.70 | 0.27 | -0.89 | -1.81 | -0.72 | 1.25 | 0.98 | 0.15 |
FCF Conversion (FCF/Net Income) | 0.99x | 1.93x | 1.33x | -0.96x | 0.61x | 0.62x | 0.10x | 3.56x | -2.66x | -0.35x |
Interest Paid | 0 | 1.64M | 2.21M | 1.98M | 1K | 16K | 11K | 434K | 0 | 0 |
Taxes Paid | 0 | 160K | 150K | 102K | 16K | 120K | 198K | 2.5M | 0 | 0 |
CSTL Key Ratios
Castle Biosciences, Inc. (CSTL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | 14.06% | -4.11% | -7.56% | -16.56% | -14.54% | 4.31% | -5.21% | -2.77% |
Return on Invested Capital (ROIC) | -44.02% | 51.5% | -56.96% | -62.53% | -28.77% | -17.07% | 1.94% | -8.52% | -5.31% |
Gross Margin | 76.75% | 85.91% | 84.54% | 83.18% | 76.64% | 79.53% | 81.87% | 79.37% | 59.31% |
Net Margin | -27.94% | 10.17% | -16.42% | -33.26% | -48.99% | -26.15% | 5.49% | -7.02% | -3.77% |
Debt / Equity | - | 0.30x | - | 0.02x | 0.03x | 0.04x | 0.06x | 0.08x | 0.08x |
Interest Coverage | -1.80x | 2.17x | -2.87x | -40011.00x | -4052.18x | -5214.00x | 38.37x | -342.19x | 270.94x |
FCF Conversion | 1.93x | 1.33x | -0.96x | 0.61x | 0.62x | 0.10x | 3.56x | -2.66x | -0.35x |
Revenue Growth | 65.67% | 127.62% | 20.79% | 50.18% | 45.65% | 60.38% | 51.09% | 3.66% | -2.06% |
Related:CSTL Dividend History·CSTL Revenue History·CSTL Price History·CSTL P/E History·CSTL Financial Ratios·CSTL Institutional Holders
CSTL SEC Filings & Documents
Castle Biosciences, Inc. (CSTL) SEC filings — annual & quarterly reports (10-K, 10-Q)
CSTL Frequently Asked Questions
Castle Biosciences, Inc. (CSTL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Castle Biosciences, Inc. (CSTL) reported $339.9M in revenue for fiscal year 2025. This represents a 2371% increase from $13.8M in 2017.
Castle Biosciences, Inc. (CSTL) grew revenue by 3.7% over the past year. Growth has been modest.
Castle Biosciences, Inc. (CSTL) reported a net loss of $12.8M for fiscal year 2025.
Dividend & Returns
Castle Biosciences, Inc. (CSTL) has a return on equity (ROE) of -5.2%. Negative ROE indicates the company is unprofitable.
Castle Biosciences, Inc. (CSTL) generated $4.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.